Atossa Therapeutics, Inc. (ATOS)

Atossa Therapeutics, Inc. (ATOS) Healthcare & Pipeline Overview

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in oncology, with a focus on breast cancer treatments. Their lead drug candidate, oral (Z)-endoxifen, targets unmet medical needs in breast cancer prevention and treatment, positioning them within a competitive biotechnology landscape.

What Is the Investment Thesis for ATOS?

Atossa Therapeutics presents a focused investment opportunity within the biotechnology sector, primarily driven by the potential of its lead drug candidate, oral (Z)-endoxifen. Currently in Phase II clinical trials, positive results could significantly increase the company's valuation. The company's focus on breast cancer, a prevalent and well-funded area of oncology, provides a clear market opportunity. However, the company's market capitalization of $20.02M reflects the inherent risks associated with clinical-stage biopharmaceutical companies, including the potential for trial failures and regulatory hurdles. The company's success hinges on the clinical trial outcomes and subsequent regulatory approvals for (Z)-endoxifen, as well as the progress of its immunotherapy programs. Investors should closely monitor clinical trial data releases and regulatory updates to assess the viability of Atossa's pipeline and its long-term growth potential.

Based on FMP financials and quantitative analysis

ATOS Key Highlights

• Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on oncology, specifically breast cancer.
• The company's lead drug candidate, oral (Z)-endoxifen, is in Phase II clinical trials for breast cancer treatment and prevention.
• Atossa is also developing immunotherapy/chimeric antigen receptor therapy programs to broaden its oncology pipeline.
• The company changed its name from Atossa Genetics Inc. to Atossa Therapeutics, Inc. in January 2020.
• Atossa Therapeutics has a market capitalization of $20.02M and a beta of 1.49.

Who Are ATOS's Competitors?

ATOS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ATOS's Key Strengths?

• Focused on a specific area of unmet medical need in oncology (breast cancer).
• Lead drug candidate (Z)-endoxifen in Phase II clinical trials.
• Developing immunotherapy/CAR therapy programs to broaden pipeline.
• Experienced management team with expertise in drug development.

What Are ATOS's Weaknesses?

• Clinical-stage company with no approved products and no revenue.
• High dependence on the success of (Z)-endoxifen.
• Limited financial resources compared to larger pharmaceutical companies.
• Small number of employees.

What Could Drive ATOS Stock Higher?

• Release of Phase II clinical trial data for oral (Z)-endoxifen.
• Initiation of new clinical trials for immunotherapy/CAR therapy programs.
• Regulatory interactions with the FDA regarding (Z)-endoxifen.
• Progress in securing strategic partnerships and collaborations.

What Are the Key Risks for ATOS?

• Financial-distress signal — its Altman Z-Score of -10.33 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-84.9%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of Phase II clinical trials for oral (Z)-endoxifen.
• Delays or rejection of regulatory approval for (Z)-endoxifen.
• Competition from other companies developing breast cancer therapies.
• Dependence on securing additional funding for research and development.
• Patent challenges to Atossa's intellectual property.

What Are the Growth Opportunities for ATOS?

• Successful Completion of Phase II Clinical Trials for (Z)-endoxifen: The primary growth opportunity for Atossa lies in the successful completion of its Phase II clinical trials for oral (Z)-endoxifen. Positive results would validate the drug's efficacy and safety, potentially leading to accelerated regulatory approval and commercialization. The breast cancer treatment market is substantial, with a global market size estimated at billions of dollars annually. A successful trial outcome could position Atossa to capture a significant share of this market, driving substantial revenue growth. The timeline for this growth is dependent on the trial's progression and subsequent regulatory review.
• Expansion of Immunotherapy/CAR Therapy Programs: Atossa's development of immunotherapy and chimeric antigen receptor (CAR) therapy programs represents another significant growth opportunity. These programs target a broader range of oncology indications, diversifying the company's pipeline and reducing its reliance on (Z)-endoxifen. The immunotherapy market is experiencing rapid growth, driven by the success of checkpoint inhibitors and other novel immunotherapies. By expanding its presence in this space, Atossa can tap into a growing market and potentially develop breakthrough treatments for various cancers. The timeline for this growth depends on the progress of preclinical and clinical development of these programs.
• Strategic Partnerships and Collaborations: Atossa can pursue strategic partnerships and collaborations with larger pharmaceutical companies or other biotech firms to accelerate the development and commercialization of its drug candidates. These partnerships can provide access to funding, expertise, and resources that Atossa may lack independently. Collaborations can also facilitate the expansion of Atossa's pipeline and market reach. The oncology market is characterized by numerous collaborations between companies, reflecting the complexity and cost of drug development. By forging strategic alliances, Atossa can enhance its competitiveness and increase its chances of success.
• Out-Licensing or Acquisition of (Z)-endoxifen: If Phase II clinical trials are successful, Atossa could pursue an out-licensing agreement with a larger pharmaceutical company to commercialize (Z)-endoxifen. This would provide Atossa with upfront payments, milestone payments, and royalties on future sales, generating significant revenue without the need for Atossa to build its own commercial infrastructure. Alternatively, Atossa could be acquired by a larger company seeking to add (Z)-endoxifen to its oncology portfolio. The timeline for this growth is dependent on the clinical trial outcomes and the interest of potential partners or acquirers.
• Expansion into International Markets: While Atossa currently focuses on the United States market, expanding into international markets represents a long-term growth opportunity. Breast cancer is a global health issue, and there is significant demand for improved treatments in many countries. By seeking regulatory approval and commercializing its drugs in international markets, Atossa can significantly increase its revenue potential. The timeline for this growth depends on the company's ability to navigate international regulatory requirements and establish distribution networks in foreign markets.

What Opportunities Does ATOS Have?

• Successful completion of Phase II clinical trials for (Z)-endoxifen.
• Expansion of immunotherapy/CAR therapy programs.
• Strategic partnerships and collaborations with larger companies.
• Out-licensing or acquisition of (Z)-endoxifen.

What Threats Does ATOS Face?

• Clinical trial failures.
• Regulatory hurdles and delays.
• Competition from other companies developing breast cancer therapies.
• Patent expiration and generic competition.

What Are ATOS's Competitive Advantages?

• Patented drug candidates, providing exclusivity and protection from competition.
• Clinical trial data demonstrating the efficacy and safety of its drugs.
• Expertise in oncology drug development and regulatory affairs.
• Established relationships with key opinion leaders in the oncology field.

What Does ATOS Do?

Atossa Therapeutics, Inc., founded in 2008 and based in Seattle, Washington, is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for oncology, with a primary focus on breast cancer. The company's origins lie in addressing unmet medical needs in women's health, evolving from Atossa Genetics Inc. to Atossa Therapeutics, Inc. in January 2020 to reflect its broader therapeutic focus. Their lead drug candidate, oral (Z)-endoxifen, an active metabolite of tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. This drug aims to improve upon existing treatments by offering a potentially more effective and tolerable option. In addition to (Z)-endoxifen, Atossa is also engaged in developing immunotherapy and chimeric antigen receptor (CAR) therapy programs, expanding its pipeline to address a wider range of oncology indications. The company operates primarily in the United States, targeting the significant market for breast cancer therapies. Atossa's strategy involves rigorous clinical trials and a commitment to advancing scientific understanding in oncology to bring novel treatments to patients.

What Products and Services Does ATOS Offer?

• Develop medicines for unmet medical needs in oncology, particularly breast cancer.
• Focus on women's health and oncology.
• Develop oral (Z)-endoxifen, an active metabolite of tamoxifen, for breast cancer treatment and prevention.
• Conduct Phase II clinical trials to evaluate the efficacy and safety of (Z)-endoxifen.
• Develop immunotherapy and chimeric antigen receptor (CAR) therapy programs.
• Seek regulatory approval for its drug candidates from the FDA and other regulatory agencies.

How Does ATOS Make Money?

• Develop and commercialize pharmaceutical products for oncology.
• Generate revenue through the sale of approved drugs.
• Out-license or partner with other companies for drug development and commercialization.
• Secure funding through venture capital, grants, and public offerings.

What Industry Does ATOS Operate In?

Atossa Therapeutics operates within the biotechnology industry, a sector characterized by high risk and high reward. The company focuses on oncology, specifically breast cancer, which remains a significant area of unmet medical need despite advancements in treatment. The competitive landscape includes major pharmaceutical companies and smaller biotech firms, all vying for market share in the oncology space. The biotechnology industry is driven by innovation, with companies like Atossa seeking to develop novel therapies that offer improved efficacy and safety profiles compared to existing treatments. The success of companies in this sector depends heavily on clinical trial outcomes, regulatory approvals, and the ability to secure funding for research and development.

Who Are ATOS's Key Customers?

• Patients with breast cancer.
• Healthcare providers who prescribe and administer cancer treatments.
• Hospitals and clinics that provide cancer care.
• Pharmaceutical companies that may partner with Atossa for drug development and commercialization.

Net buyingInsider Activity

Over the past six months, Atossa Therapeutics, Inc. insiders filed 11 SEC Form 4 transactions — 0 sales and 11 purchases. On net that is roughly 1.8M shares acquired (about $573K) — insiders putting money in tends to read as conviction.

ATOS Valuation & Market Position

With a $20.02M market cap, Atossa Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, ATOS's quantitative score of 29/100 is below the peer average of 80/100.

ROE -85%Key Financial Metrics

Return on equity for Atossa Therapeutics, Inc. stands at -84.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -99.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -85.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.92 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -95.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Atossa Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -10.33 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Atossa Therapeutics, Inc. revenue of about $54.5M for fiscal 2026, with EPS near $-4.33. The estimate reflects 3 contributing analysts.

Company Profile

Atossa Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Steven C. Quay. ATOS has traded publicly since 2012.

ATOS Financials

ATOS Latest News

ATOS Analyst Consensus

ATOS MoonshotScore

Latest Atossa Therapeutics, Inc. Analysis

What Investors Ask About Atossa Therapeutics, Inc. (ATOS) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources